» Articles » PMID: 26240275

Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia

Abstract

Purpose: ROR1, a receptor in the noncanonical Wnt/planar cell polarity (PCP) pathway, is upregulated in malignant B cells of chronic lymphocytic leukemia (CLL) patients. It has been shown that the Wnt/PCP pathway drives pathogenesis of CLL, but which factors activate the ROR1 and PCP pathway in CLL cells remains unclear.

Experimental Design: B lymphocytes from the peripheral blood of CLL patients were negatively separated using RosetteSep (StemCell) and gradient density centrifugation. Relative expression of WNT5A, WNT5B, and ROR1 was assessed by quantitative real-time PCR. Protein levels, protein interaction, and downstream signaling were analyzed by immunoprecipitation and Western blotting. Migration capacity of primary CLL cells was analyzed by the Transwell migration assay.

Results: By analyzing the expression in 137 previously untreated CLL patients, we demonstrate that WNT5A and WNT5B genes show dramatically (five orders of magnitude) varying expression in CLL cells. High WNT5A and WNT5B expression strongly associates with unmutated IGHV and shortened time to first treatment. In addition, WNT5A levels associate, independent of IGHV status, with the clinically worst CLL subgroups characterized by dysfunctional p53 and mutated SF3B1. We provide functional evidence that WNT5A-positive primary CLL cells have increased motility and attenuated chemotaxis toward CXCL12 and CCL19 that can be overcome by inhibitors of Wnt/PCP signaling.

Conclusions: These observations identify Wnt-5a as the crucial regulator of ROR1 activity in CLL and suggest that the autocrine Wnt-5a signaling pathway allows CLL cells to overcome natural microenvironmental regulation.

Citing Articles

Role of the Ror family receptors in Wnt5a signaling.

Kamizaki K, Minami Y, Nishita M In Vitro Cell Dev Biol Anim. 2024; 60(5):489-501.

PMID: 38587578 DOI: 10.1007/s11626-024-00885-4.


Prognostic Value of the Expression of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) in Chronic Lymphocytic Leukemia.

Yikilmaz A, Bakanay S, Avci D, Akinci S, Falay M, Ozet G Int J Hematol Oncol Stem Cell Res. 2023; 17(1):39-47.

PMID: 37638287 PMC: 10448922. DOI: 10.18502/ijhoscr.v17i1.11712.


Role of casein kinase 1 in the amoeboid migration of B-cell leukemic and lymphoma cells: A quantitative live imaging in the confined environment.

cada S, Vondalova Blanarova O, Gomoryova K, Mikulova A, Bacovska P, Zezula N Front Cell Dev Biol. 2022; 10:911966.

PMID: 36561363 PMC: 9763939. DOI: 10.3389/fcell.2022.911966.


Evaluation of miRNA 223/125a and COBLL1 Expressions and ROR-1 Levels as Reliable Markers in B- chronic Lymphocytic Leukemia.

Hussein S, Abdelazem A, Abdelmoneem S, Abdelnabi A, Khamis T, Obaya A Asian Pac J Cancer Prev. 2022; 23(8):2735-2742.

PMID: 36037128 PMC: 9741902. DOI: 10.31557/APJCP.2022.23.8.2735.


Immunoglobulin Gene Sequence as an Inherited and Acquired Risk Factor for Chronic Lymphocytic Leukemia.

Datta M, Jumaa H Cancers (Basel). 2022; 14(13).

PMID: 35804817 PMC: 9264995. DOI: 10.3390/cancers14133045.


References
1.
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2001; 343(26):1910-6. DOI: 10.1056/NEJM200012283432602. View

2.
Baliakas P, Hadzidimitriou A, Sutton L, Rossi D, Minga E, Villamor N . Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2014; 29(2):329-36. DOI: 10.1038/leu.2014.196. View

3.
Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

4.
Richardson S, Matthews C, Catherwood M, Alexander H, Carey B, Farrugia J . ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2005; 107(9):3584-92. DOI: 10.1182/blood-2005-04-1718. View

5.
Bryja V, Schulte G, Arenas E . Wnt-3a utilizes a novel low dose and rapid pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to activate beta-catenin. Cell Signal. 2006; 19(3):610-6. DOI: 10.1016/j.cellsig.2006.08.011. View